Relmada Therapeutics, Inc. (NASDAQ:RLMD, “Relmada” or the “Company”))), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution.
Recent Posts
- Ballard Power Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts
- Elon Musk Admits Tesla Cybercab’s $300 Monthly Fee Is Too High — MKBHD Says His Headshave Bet Isn’t Over as Deliveries Remain Invite-Only
- Fiscal Hawk Rips Democrats’ Offset Claims: ‘I’m Sorry, Infrastructure?’
- Intel Stock Down 3.8% Overnight on Robinhood as Lip-Bu Tan Faces Lawsuit Over PC Slowdown Disclosure
- Home Depot Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Archives
- November 2026
- October 2026
- September 2026
- August 2026
- July 2026
- June 2026
- May 2026
- April 2026
- March 2026
- February 2026
- January 2026
- December 2025
- November 2025
- October 2025
- September 2025
- August 2025
- July 2025
- June 2025
- May 2025
- April 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
Recent Comments